Clinical Research Trials - Hausarzt|Stuttgart| Moenchfeld|Praevention|Schulung|Studien|

Akademische Lehrpraxis der medizinischen Fakultät der Eberhard Karls Universität Tübingen
Akademische Forschungspraxis der medizinischen Fakultät der Ruprecht-Karls-Universität Heidelberg
Direkt zum Seiteninhalt

Clinical Research Trials

letzte Änderung  12.02.2018

EudraCT Nr. 2016-004965-22, Diabetes, Novo Nordisk, Phase III (since 2017 ongoing)
Efficacy and safety of semaglutide 1,0 mg once-weekly versus liraglutide 1,2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes.

EudraCT Nr. 2014-005671-92, COPD, Pearl Therapeutics, Phase III (since 2017 ongoing)
A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and mPT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.

EudraCT Nr. 2016-003084-19, Diabetes, Novartis, Phase II (since 2017 ongoing)
A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to plebo or empagliflozin in type 2 diabetes mellitus patients with heart failure.

EudraCT Nr. 2015-001351-71, Diabetes, Novo Nordisk, Phase III (2015-2017)
Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.

EudraCT Nr. 2014-001540-38, Obesity, Novo Nordisk, Phase II (2015-2017)
Investigation of safety and efficacy of once-daily semiglutide in obese subjects without diabetes mellitus - A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, multi-centre, multinational trial with liraglutide 3.0 mg as active comparator.

EudraCT Nr. 2014-001824-32, Diabetes, GlaxoSmithKline UK, Phase IV (since 2015 ongoing)
A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus.

EudraCT Nr. 2014-003196-39, Diabetes, Novo Nordisk, Phase II (2015-2016)
Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes.

EudraCT Nr. 2014-002844-42, Diabetes, Sanofi, Phase III (2015-2016)
Six-month, randomized, open-label, parallel-group comparison oft the insulin analog SAR342434 to Humalog in adult patients with type 2 diabetes mellitus also using insulin glargine.

EudraCT Nr. 2014-002253-19, Asthma, GlaxoSmithKline UK, Phase III (2015)
A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Proprionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fltuicasone Proprionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhalde corticosteroid and long-acting beta2 agonist.

EudraCT Nr. 2013-004502-26, Diabetes, Novo Nordisk, Phase III (2014-2015)

Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with typ 2 diabetes.


EudraCT Nr. 2013-003075-35, COPD, GlaxoSmithKline UK, Phase III (2014-2015)
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.

EudraCT Nr. 2013-004392-12
, Diabetes, Novo Nordisk, Phase III (2014-2015)
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes.

EudraCT Nr. 2013-004297-98, COPD, GlaxoSmithKline UK, Phase III (2014-2015)
Study MEA117113: Mepalizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.

EudraCT Nr. 2013-001473-24
, Diabetes, Eli Lilly, Phase IV (2014-2015)
An individualized treatment approach for older patients: A randomized, controlled study in type 2 diabetes mellitus.

EudraCT Nr. 2013-002239-44
, COPD, GlaxoSmithKline UK, Phase III (2013-2014)
A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VL in subjects with Chronic Obstructive Pulmonary Disease (COPD).

EudraCT Nr. 2006-003622-29
, Cardiovascular Disease, Bayer, Phase III (2008-2017)
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardivascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicyl Acid in Patients at Moderate Risk of Cardiovascular Disease.

EudraCT Nr. 2008-004104-31
, Chronic heart failure, Novartis, Phase III (2009-2015)
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II-IV).

PraCMan
, University of Heidelberg, (2011-2013)
Primary care practice-based care management for chronically ill patients.

EudraCT-Nr. 2012-001870-27
, COPD, GlaxoSmithKline UK, Phase III (2013)
A randomized, double-blind, parallel group study to evaluate the efficacy and safety of fluticasone propionate/salmeterol 250/50mcg twice-daily plus GSK573719 Inhalation Powder 62.5mcg once-daily or GSK573719 Inhalation Powder 125mcg once-daily in subjects with COPD.

EudraCT Nr. 2008-002199-88
, Diabetes, Novo Nordisk, Phase III (2011-2013)
Effect of liraglutide on body weight in overweight or obese sujects with type 2 diabetes. A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow up period.

EudraCT Nr. 2010-021560-15
, Diabetes, Novo Nordisk, Phase III (2011-2012)
A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs.

EudraCT Nr. 2010-021800-72
, COPD, GlaxoSmithKline UK, Phase III (2011-2012)
A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in sujects with COPD.

EudraCT Nr. 2011-000518-21
, Diabetes, Novartis, Phase IV (2011-2012)
Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT).

EudraCT Nr. 2009-010913-59
, Diabetes, Sanofi-Aventis, Phase IV (2011-2012)
Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin gl...

EudraCT Nr. 2008-007831-41
, Hypertension, Novartis, Phase IV (2009-2010)
A twelve-week, randomized, double-blind, parallel group study to evaluate th prolonged efficacy and safety of aliskiren 300 g compared to telmisartan 80 mg in mild to moderate hypertensive patients.

getABI
, epidemiological trial, (2002-2008)
German epidemiological trial on ankle brachial index for elderly patients in family practice to dedect peripheral arterial disease, significant marker for high mortality.



Zurück zum Seiteninhalt